Weekly insulin shot could replace daily jabs for diabetes

NCT ID NCT06767748

Ongoing Disease control Sponsor: Gan & Lee Pharmaceuticals. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 study tests a new insulin called GZR4 that is injected just once a week, compared to the standard daily insulin degludec. About 620 adults with type 2 diabetes who already use basal insulin will take part. The goal is to see if the weekly shot controls blood sugar just as well, with similar safety and fewer injections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GZR4 (a once-weekly insulin injection)
What this could lead to: If it works, this could offer a more convenient once-weekly insulin option for people with type 2 diabetes, reducing daily injections.
What could go wrong: This is a phase 3 trial, but it's still experimental. The new insulin may not control blood sugar as well as daily insulin, or could cause different side effects like hypoglycemia or weight changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus Insulin Resistance type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES

Contacts and locations

Locations

Gan & Lee Pharmaceuticals Shandong Co., Ltd.

Linyi, Shandong, 276000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.